(AKZA) Akzo Nobel - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0013267909
Stock: Paints, Coatings, Powder Coatings
Total Rating 32
Risk 68
Buy Signal -1.42
| Risk 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Relative Tail Risk | -6.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.55 |
| Alpha | -25.59 |
| Character TTM | |
|---|---|
| Beta | 0.475 |
| Beta Downside | 0.653 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.78% |
| CAGR/Max DD | -0.23 |
EPS (Earnings per Share)
Revenue
Description: AKZA Akzo Nobel March 05, 2026
Akzo Nobel N.V. (AKZA) is a Dutch company specializing in paints and coatings. It operates globally through two segments: Decorative Paints and Performance Coatings. The Decorative Paints segment offers products like paints, lacquers, and varnishes for the building and renovation sector. The Performance Coatings segment provides protective and enhancing coatings for diverse applications, including marine vessels, automobiles, and industrial facilities. The companys business model involves a broad portfolio of brands catering to various industries, including energy, packaging, and shipbuilding. The coatings industry is characterized by a need for continuous innovation in product formulation and application.
Founded in 1646, Akzo Nobel N.V. serves a wide array of general industries such as agricultural equipment, construction-related steel, and transportation. The companys extensive brand list demonstrates its market penetration across different product categories and geographies. Understanding the specific market share of these brands can provide further insights. For more detailed analysis, consider exploring ValueRays comprehensive data.
Headlines to watch out for
- Raw material price volatility impacts profit margins
- Global construction and automotive demand drives coatings sales
- Currency fluctuations affect international revenue translation
- Environmental regulations increase compliance costs
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 635.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 18.25% < 20% (prev 10.33%; Δ 7.93% < -1%) |
| CFO/TA 0.07 > 3% & CFO 915.0m > Net Income 635.0m |
| Net Debt (3.24b) to EBITDA (1.54b): 2.10 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.8m) vs 12m ago 0.61% < -2% |
| Gross Margin: 39.86% > 18% (prev 0.40%; Δ 3.95k% > 0.5%) |
| Asset Turnover: 72.04% > 50% (prev 75.17%; Δ -3.13% > 0%) |
| Interest Coverage Ratio: 6.26 > 6 (EBITDA TTM 1.54b / Interest Expense TTM 186.0m) |
Altman Z'' 2.16
| A: 0.13 (Total Current Assets 6.06b - Total Current Liabilities 4.21b) / Total Assets 13.95b |
| B: 0.04 (Retained Earnings 559.0m / Total Assets 13.95b) |
| C: 0.08 (EBIT TTM 1.16b / Avg Total Assets 14.10b) |
| D: 0.57 (Book Value of Equity 5.22b / Total Liabilities 9.13b) |
| Altman-Z'' Score: 2.16 = BBB |
Beneish M -2.92
| DSRI: 1.21 (Receivables 2.61b/2.27b, Revenue 10.16b/10.71b) |
| GMI: 1.02 (GM 39.86% / 40.49%) |
| AQI: 0.95 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 0.95 (Revenue 10.16b / 10.71b) |
| TATA: -0.02 (NI 635.0m - CFO 915.0m) / TA 13.95b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of AKZA shares?
As of March 15, 2026, the stock is trading at EUR 52.00 with a total of 558,638 shares traded.
Over the past week, the price has changed by -2.21%, over one month by -15.55%, over three months by -9.61% and over the past year by -11.63%.
Over the past week, the price has changed by -2.21%, over one month by -15.55%, over three months by -9.61% and over the past year by -11.63%.
Is AKZA a buy, sell or hold?
Akzo Nobel has no consensus analysts rating.
What are the forecasts/targets for the AKZA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.3 | 31.3% |
| Analysts Target Price | - | - |
AKZA Fundamental Data Overview March 10, 2026
Market Cap USD = 10.38b (8.98b EUR * 1.1554 EUR.USD)
P/E Trailing = 14.1946
P/E Forward = 12.9366
P/S = 0.8845
P/B = 1.9284
P/EG = 1.0106
Revenue TTM = 10.16b EUR
EBIT TTM = 1.16b EUR
EBITDA TTM = 1.54b EUR
Long Term Debt = 3.48b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.19b EUR (from shortTermDebt, last quarter)
Debt = 4.86b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.24b EUR (from netDebt column, last quarter)
Enterprise Value = 11.93b EUR (8.98b + Debt 4.86b - CCE 1.92b)
Interest Coverage Ratio = 6.26 (Ebit TTM 1.16b / Interest Expense TTM 186.0m)
EV/FCF = 19.68x (Enterprise Value 11.93b / FCF TTM 606.0m)
FCF Yield = 5.08% (FCF TTM 606.0m / Enterprise Value 11.93b)
FCF Margin = 5.97% (FCF TTM 606.0m / Revenue TTM 10.16b)
Net Margin = 6.25% (Net Income TTM 635.0m / Revenue TTM 10.16b)
Gross Margin = 39.86% ((Revenue TTM 10.16b - Cost of Revenue TTM 6.11b) / Revenue TTM)
Gross Margin QoQ = 39.46% (prev 40.32%)
Tobins Q-Ratio = 0.85 (Enterprise Value 11.93b / Total Assets 13.95b)
Interest Expense / Debt = 0.88% (Interest Expense 43.0m / Debt 4.86b)
Taxrate = 18.77% (140.0m / 746.0m)
NOPAT = 945.6m (EBIT 1.16b * (1 - 18.77%))
Current Ratio = 1.44 (Total Current Assets 6.06b / Total Current Liabilities 4.21b)
Debt / Equity = 1.04 (Debt 4.86b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.10 (Net Debt 3.24b / EBITDA 1.54b)
Debt / FCF = 5.35 (Net Debt 3.24b / FCF TTM 606.0m)
Total Stockholder Equity = 4.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 635.0m / Total Assets 13.95b)
RoE = 14.61% (Net Income TTM 635.0m / Total Stockholder Equity 4.35b)
RoCE = 14.88% (EBIT 1.16b / Capital Employed (Equity 4.35b + L.T.Debt 3.48b))
RoIC = 21.08% (NOPAT 945.6m / Invested Capital 4.49b)
WACC = 5.22% (E(8.98b)/V(13.85b) * Re(7.66%) + D(4.86b)/V(13.85b) * Rd(0.88%) * (1-Tc(0.19)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF] Terminal Value 83.93% ; FCFF base≈510.4m ; Y1≈413.3m ; Y5≈287.1m
[DCF] Fair Price = 32.52 (EV 8.81b - Net Debt 3.24b = Equity 5.56b / Shares 171.1m; r=5.90% [WACC]; 5y FCF grow -22.80% → 2.90% )
EPS Correlation: -26.93 | EPS CAGR: -10.81% | SUE: -0.26 | # QB: 0
Revenue Correlation: -50.30 | Revenue CAGR: -1.65% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.20 | Chg7d=-0.020 | Chg30d=-0.112 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=4.14 | Chg7d=-0.023 | Chg30d=-0.200 | Revisions Net=-13 | Growth EPS=+13.9% | Growth Revenue=-2.1%
EPS next Year (2027-12-31): EPS=4.55 | Chg7d=-0.014 | Chg30d=-0.207 | Revisions Net=-9 | Growth EPS=+10.0% | Growth Revenue=+2.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.9% (Discount Rate 7.9% - Earnings Yield 7.0%)
[Growth] Growth Spread = -6.0% (Analyst -5.1% - Implied 0.9%)
P/E Trailing = 14.1946
P/E Forward = 12.9366
P/S = 0.8845
P/B = 1.9284
P/EG = 1.0106
Revenue TTM = 10.16b EUR
EBIT TTM = 1.16b EUR
EBITDA TTM = 1.54b EUR
Long Term Debt = 3.48b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.19b EUR (from shortTermDebt, last quarter)
Debt = 4.86b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.24b EUR (from netDebt column, last quarter)
Enterprise Value = 11.93b EUR (8.98b + Debt 4.86b - CCE 1.92b)
Interest Coverage Ratio = 6.26 (Ebit TTM 1.16b / Interest Expense TTM 186.0m)
EV/FCF = 19.68x (Enterprise Value 11.93b / FCF TTM 606.0m)
FCF Yield = 5.08% (FCF TTM 606.0m / Enterprise Value 11.93b)
FCF Margin = 5.97% (FCF TTM 606.0m / Revenue TTM 10.16b)
Net Margin = 6.25% (Net Income TTM 635.0m / Revenue TTM 10.16b)
Gross Margin = 39.86% ((Revenue TTM 10.16b - Cost of Revenue TTM 6.11b) / Revenue TTM)
Gross Margin QoQ = 39.46% (prev 40.32%)
Tobins Q-Ratio = 0.85 (Enterprise Value 11.93b / Total Assets 13.95b)
Interest Expense / Debt = 0.88% (Interest Expense 43.0m / Debt 4.86b)
Taxrate = 18.77% (140.0m / 746.0m)
NOPAT = 945.6m (EBIT 1.16b * (1 - 18.77%))
Current Ratio = 1.44 (Total Current Assets 6.06b / Total Current Liabilities 4.21b)
Debt / Equity = 1.04 (Debt 4.86b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.10 (Net Debt 3.24b / EBITDA 1.54b)
Debt / FCF = 5.35 (Net Debt 3.24b / FCF TTM 606.0m)
Total Stockholder Equity = 4.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 635.0m / Total Assets 13.95b)
RoE = 14.61% (Net Income TTM 635.0m / Total Stockholder Equity 4.35b)
RoCE = 14.88% (EBIT 1.16b / Capital Employed (Equity 4.35b + L.T.Debt 3.48b))
RoIC = 21.08% (NOPAT 945.6m / Invested Capital 4.49b)
WACC = 5.22% (E(8.98b)/V(13.85b) * Re(7.66%) + D(4.86b)/V(13.85b) * Rd(0.88%) * (1-Tc(0.19)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF] Terminal Value 83.93% ; FCFF base≈510.4m ; Y1≈413.3m ; Y5≈287.1m
[DCF] Fair Price = 32.52 (EV 8.81b - Net Debt 3.24b = Equity 5.56b / Shares 171.1m; r=5.90% [WACC]; 5y FCF grow -22.80% → 2.90% )
EPS Correlation: -26.93 | EPS CAGR: -10.81% | SUE: -0.26 | # QB: 0
Revenue Correlation: -50.30 | Revenue CAGR: -1.65% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.20 | Chg7d=-0.020 | Chg30d=-0.112 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=4.14 | Chg7d=-0.023 | Chg30d=-0.200 | Revisions Net=-13 | Growth EPS=+13.9% | Growth Revenue=-2.1%
EPS next Year (2027-12-31): EPS=4.55 | Chg7d=-0.014 | Chg30d=-0.207 | Revisions Net=-9 | Growth EPS=+10.0% | Growth Revenue=+2.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.9% (Discount Rate 7.9% - Earnings Yield 7.0%)
[Growth] Growth Spread = -6.0% (Analyst -5.1% - Implied 0.9%)